Patents by Inventor Michael Hundemer

Michael Hundemer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND ENZYME SOLUTION FOR FLOW-CYTOMETRIC DETECTION OF LIGHT CHAIN RESTRICTION
    Publication number: 20170204450
    Abstract: The invention relates to an enzyme solution, which is used preferably for pre-treating mammalian cells for flow-cytometric detection of light chain restriction of the cells, the enzyme solution comprising at least two proteases, which are proteolytic and also collagenolytic, in a buffer. Preferably, the enzyme solution comprises trypsin, collagenase 4, dispase and astacin. The invention also relates to uses of the enzyme solution and methods for flow-cytometric detection of light chain restriction of cells.
    Type: Application
    Filed: May 28, 2015
    Publication date: July 20, 2017
    Inventors: Stefan KRIENKE, Michael HUNDEMER
  • Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)
    Patent number: 9011867
    Abstract: The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: April 21, 2015
    Assignee: Ruprecht-Karls-Universitat Heidelberg
    Inventors: Michael Hundemer, Olaf Christensen
  • USE OF SPECIFIC PEPTIDES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) OR OF SMOLDERING MULTIPLE MYELOMA (SMM)
    Publication number: 20120114681
    Abstract: The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells.
    Type: Application
    Filed: February 1, 2010
    Publication date: May 10, 2012
    Inventors: Michael Hundemer, Olaf Christensen